Harmony Biosciences (HRMY) vs NewAmsterdam Pharma N.V. (NAMS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Harmony Biosciences (HRMY) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, gaining 49.1% versus a loss of 35.3%. Over five years, NAMS leads with a +117.2% price change compared with +0.5% for HRMY. NewAmsterdam Pharma N.V. is the larger company by market cap ($2.52 billion vs $2.35 billion), about 1.1 times the size, while Harmony Biosciences is growing revenue faster (+21.5% vs -50.6%).
Harmony Biosciences converts more of its revenue into profit, with a net margin of 18.3% versus -905.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRMY | NAMS |
|---|---|---|
| Share price | $40.28 | $21.58 |
| Market cap | $2.35B | $2.52B |
| 1-day change | +1.72% | +1.48% |
| YTD return | +5.83% | -39.40% |
| 1-year return | +49.10% | -35.30% |
| 5-year return | +0.51% | +117.16% |
| P/E ratio (TTM) | 12.99 | — |
| Forward P/E | 5.75 | — |
| EPS (TTM) | $3.10 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $868.45M | $22.50M |
| Revenue growth (YoY) | +21.51% | -50.61% |
| Net income (latest FY) | $158.69M | $-203.82M |
| Gross margin | 77.16% | — |
| Operating margin | 24.00% | -1002.90% |
| Net margin | 18.27% | -905.74% |
| 52-week high | $43.49 | $42.21 |
| 52-week low | $25.52 | $20.91 |
| Distance from 52-week high | -7.38% | -48.88% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +18.27% | +130.13% |
| Average volume | 892.55K | 1.36M |
| Shares outstanding | 58.24M | 116.90M |
| Employees | 293 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HRMY has outperformed NAMS by 84.4 percentage points over the past year.
- Harmony Biosciences is more profitable, keeping 18.3 cents of every revenue dollar as net income versus -905.7 cents for NewAmsterdam Pharma N.V..
- Harmony Biosciences grew revenue faster in its latest fiscal year (+21.51% vs -50.61%).
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
HRMY vs NAMS FAQ
Which is bigger, Harmony Biosciences or NewAmsterdam Pharma N.V.?
NewAmsterdam Pharma N.V. (NAMS) is larger, with a market capitalization of $2.52B compared with $2.35B for Harmony Biosciences (HRMY).
Which stock has performed better over the past year, HRMY or NAMS?
HRMY returned +49.10% over the past 12 months, compared with -35.30% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are Harmony Biosciences and NewAmsterdam Pharma N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.